AZD7442

Background: AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

Phase 3

Completed

Phase 2

Completed

Interventions: Biological: bamlanivimab 7000mg
Drug: Placebo for Bamlanivimab 7000mg
Biological: bamlanivimab 700mg
Drug: Placebo for Bamlanivimab 700mg
Biological: BRII-196+BRII-198
Drug: Placebo for BRII-196+BRII-198
Biological: AZD7442 (IV)
Biological: AZD7442 (IM)
Drug: Placebo for SNG001
Drug: Placebo for Camostat
Biological: SAB-185 (3,840 Units/kg)
Drug: Placebo for SAB-185 (low dose)
Biological: SAB-185 (10,240 Units/kg)
Drug: Placebo for SAB-185 (high dose)
Biological: BMS-986414 + BMS-986413
Drug: Placebo for BMS-986414 + BMS-986413
Drug: CASIRIVIMAB + IMDEVIMAB
Drug: Placebo for AZD7442 (IV)
Drug: Placebo for AZD7442 (IM)
Drug: SNG001
Drug: Camostat

Locations: 🇺🇸
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States
🇺🇸
Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.